Life sciences consultancy and market access specialist secures investment from global private equity firm

Transaction

Investment in Newmarket Strategy from Baird Capital

Buy-side

Undisclosed

Role

Adviser to Baird Capital on its investment in Newmarket Strategy

Sector

Healthcare

Region

We have advised Baird Capital on its investment in Newmarket Strategy (Newmarket), an independent life sciences consultancy and market access specialist. The investment from Baird Capital will support Newmarket’s continued growth as an independent leader in pharmaceutical services and healthcare advisory.

Founded in 2021, Newmarket provides deep market access as well as commercial and policy expertise to the health and life sciences sector. The business works with clients to assess market opportunities, secure reimbursement from national and local payors, and drive the uptake of health innovations. Newmarket’s clients include global pharmaceuticals and biotech, med-tech, diagnostics, digital health, private equity, and healthcare services providers.

Our team provided Baird Capital with M&A services and strategic analysis to support the transaction.

group healthcare workers businessman using laptop

We are thrilled to partner with Baird Capital for Newmarket’s next stage of growth. We were hugely impressed by Baird Capital’s team and partnership style, by their proven expertise and by the commitment they show to our sector. We are immensely proud of the hard work by all our team to date and of the continued faith shown by our valued clients.
Ed Jones, Chief Executive, Newmarket Strategy

We are excited to support Newmarket’s ambition to be the leader in its field. The team brings a high level of expertise, and the services they provide address a critical need across the clients they serve. This investment in Newmarket follows a number of previous investments that we have made in the Pharma Services segment including Campbell Alliance, Prescient, and Blue Matter. We look forward to working with Ed and the team to grow Newmarket over the upcoming years.
Michael Holgate, Partner with Baird Capital’s Global Private Equity team

It has been a pleasure to advise Baird Capital on their investment in Newmarket, which represents our latest transaction in the market access sector. Newmarket’s unique proposition, strong reputation and dedication to supporting its customers to navigate the UK’s complex commissioning, value assessment and procurement landscape aligns well with Baird Capital’s strategic vision. We are proud to have advised them on this partnership.
Will Arnold, Director, Clearwater

Advisers

Marcus Archer

Managing Director +44 845 052 0379 marcus.archer@clearwatercf.com Connect

Will Arnold

Director +44 845 872 3793 will.arnold@clearwatercf.com Connect

Cameron Hannah

Senior Associate +44 845 052 0302 cameron.hannah@clearwatercf.com

Transactions

Creating a stronger future for fertility care

Adviser to Manchester Fertility Group on its sale to Amulet Capital Partners-backed TFP Fertility Group

Ireland's leading occupational healthcare provider secures strategic investment from mid-market private equity

Adviser to Medmark on its investment from Phoenix Equity Partners

Refinancing enhances capacity for growth in health and life sciences advisory market

Adviser to Baird Capital-backed Newmarket Strategy

pharmaceutical bottling process modern industrial production

Landmark investment in UK life sciences market access technology and consultancy

Adviser to Access Infinity on its investment from CBPE Capital

View all